Fresenius Kabi SwissBioSim GmbH et al. v. Regeneron Pharmaceuticals, Inc.

IPR2025-01268

Fresenius Kabi SwissBioSim petitions the PTAB to invalidate Regeneron’s anti‑VEGF eye‑drug patent, asserting that the Dix ’226 reference anticipates all challenged claims and that the patent owner has not shown any criticality for the claimed formulation parameters.

Jurisdiction
US PTAB
Case Number
IPR2025-01268
Filing Date
14 July 2025
Status
ok

Related Cases

patentIPR2025-00907

Apple Inc.vsApex Beam Technologies LLC

Apple Inc. successfully demonstrated a reasonable likelihood of prevailing in its IPR against Apex Beam Technologies LLC regarding claims 1-20 of U.S. Patent No. 11139944. The Board found that the combination of 3GPP standards documents renders the claims obvious under 35 U.S.C. § 103, leading to institution of trial.

patentIPR2025-00573

Alliance Laundry Systems, LLCvsPayRange LLC.

Alliance Laundry Systems' IPR petition against PayRange LLC was denied, finding no reasonable likelihood that claims 7 and 11 were unpatentable under 35 U.S.C. § 103. The Board rejected arguments combining prior art references (Low, Arora, Freeny, Casey) to establish obviousness.

patentIPR2025-01270

Samsung Electronics Co., Ltd. et al.vsXiFi Networks R&D, Inc.

XiFi Networks seeks an out‑of‑time Director Review to vacate the institution of eleven IPRs and PGRs against Samsung, arguing that Samsung’s contradictory claim‑construction positions in district court and before the PTAB violate recent Revvo precedent.

patentIPR2025-00008

T-Mobile USA, Inc. et al.vsAspen Networks, Inc.

T-Mobile USA's IPR challenge against Aspen Networks regarding VoIP network routing claims was denied by the PTAB. The Board found that the petitioner failed to demonstrate a reasonable likelihood of success on its obviousness grounds, specifically concerning how SIP signaling sequences are maintained across network handoffs.

patentIPR2025-01431

Samsung Electronics Co., Ltd. et al.vsNetlist, Inc.

The PTAB held that Samsung and its co‑petitioners proved all 35 claims of Netlist’s ’339 memory‑module patent were obvious over the Ellsberry and Halbert references, rendering the claims unpatentable.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call